Abstract 581P
Background
Although colorectal cancer (CRC) survivors often suffer from defecation related symptoms (DRS), there are very few treatment options to improve DRS. Strengthening of abdominal muscles to increase intra-abdominal pressure and pelvic floor exercises to improve pelvic floor dyssynergia may improve DRS in colorectal cancer patients. However, the effects of exercise on DRS have not been studied fully. Therefore, the purpose of this study is to investigate the efficacy of exercise on DRS in CRC.
Methods
A total of 120 CRC who completed surgery and adjuvants therapy were recruited out of 441 approached. 120 participants were randomly assigned to either exercise (EG) or usual care group (CG). The combined weekly supervised and home-based exercise program (12 weeks) includes increase in physical activity (PA) levels to meet the ACSM guideline as well as daily calisthenics exercises. Calisthenics exercises include a total of 12 movements aimed to increase whole body muscle strengths which focused on core and pelvic floor muscles. The primary outcome was DRS score assessed the sum of blood and mucus in stool, stool frequency, abdominal pain, buttock pain, bloating, flatulence, fecal incontinence and embarrassment in EOTRC-QLQ-CR29. A two-way ANOVA repeated measures were used determine group and time interaction. Table: 581P
Effects of exercise on defecatory symptoms
Control | Exercise | p-value | |||
Pre | Post | Pre | Post | ||
Blood in stool | 4.7 ± 9.7 | 4.4 ± 9.1 | 7.2 ± 15.5 | 3.1 ± 8.9 | 0.05 |
Stool frequency | 26.3 ± 27.0 | 20.1 ± 20.5 | 28.7 ± 25.1 | 23.4 ± 23.8 | 0.91 |
Abdominal pain | 14.4 ± 22.4 | 11.7 ± 19.2 | 18.3 ± 24.9 | 10.0 ± 16.6 | 0.21 |
Buttock pain | 12.2 ± 21.2 | 12.8 ± 25.4 | 18.9 ± 30.3 | 12.8 ± 26.1 | 0.08 |
Bloating | 22.8 ± 22.5 | 25.0 ± 25.8 | 34.4 ± 30.7 | 22.8 ± 27.1 | 0.01 |
Flatulence | 21.0 ± 26.0 | 17.7 ± 23.3 | 28.3 ± 33.5 | 21.5 ± 25.1 | 0.42 |
Fecal incontinence | 13.5 ± 20.5 | 13.1 ± 20.5 | 16.9 ± 24.8 | 12.9 ± 25.3 | 0.26 |
Embarrassment | 20.4 ± 26.8 | 16.7 ± 20.8 | 27.6 ± 32.0 | 18.0 ± 25.5 | 0.16 |
Bolds were statistically significant different between pre and post (p<.05), p= Difference between control vs. exercise
Results
Among the 120 participants enrolled, 100 (96.6%) completed the trial with supervised exercise compliance rate of 95%. PA levels increased and fitness levels improved only in the exercise group. Exercise significantly decreased DRS score (6 week - 0 week: CG= -14.0 ± 54.7 vs. EG= - 56.1 ± 99.5, p for group and time interaction = 0.02). Symptom scores in EG include blood and mucus in stool, abdominal pain, buttock pain, bloating, flatulence and embarrassment were improved.
Conclusions
It is concluded that both combined supervised and home-based exercise significantly reduced bowel and defecatory problems in colorectal cancer patients.
Clinical trial identification
This study was approved by The Institutional Review Board of Severance Hospital (IRB No. 4-2018-0841).
Editorial acknowledgement
This study was funded by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0012020020) and Yonsei Signature Research Cluster Program of 2021-22-0009.
Legal entity responsible for the study
The authors.
Funding
The National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea, Yonsei Signature Research Cluster Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10